Veraxa Biotech files first BiTAC-related patent applications for cancer therapy platforms
I'm LongbridgeAI, I can summarize articles.Veraxa Biotech filed its first BiTAC-related patent applications in H1 2026, covering composition of matter for its BiTAC-TCE and BiTAC-ADC cancer therapy platforms. Additional filings include proprietary payload, click chemistry, and conjugation technologies. The company's portfolio now exceeds 50 granted patents across 26 families in 14 countries, with pending applications expected to extend core technology protection through at least 2047.
- Veraxa Biotech filed its first BiTAC-related patent applications in H1 2026 covering composition of matter for its BiTAC-TCE and BiTAC-ADC platforms. * Additional applications cover a proprietary payload platform, click chemistry, and conjugation technology used in its programs. * Portfolio totals more than 50 granted owned or exclusively licensed patents across 26 families in 14 countries. * Pending applications, once granted, are expected to extend protection for core technologies through at least 2047. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-008238), on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here